For MBM patients, an important study of immunotherapy combined with targeted drugs was performed in the TRICOTEL trial, which showed that the addition of atezolizumab (anti-PD-L1) to vemurafenib (BRAFi) or cobimetinib (MEKi) provided promising intracranial activity in patients with BRAF V600-mutated melanoma with CNS metastases, the intracranial ORR was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAF V600 wild-type cohort (44). This evidence concerns the gene BRAF and melanoma.